Genmab — December 2016
-
Synes at der blev sådan en ro efter I så lukkekursen
nå ja men det skal jo nok også lige fordøjes
NBI lukkede pænt oppe, så mon ikke det bliver godt igen (på et tidspunkt) ? Imponerende som AB fik købt en masse billige aktier tilbage i lukkeaktionen. -
Salgstal 21. december
-
- dec
-
Godmorgen. Duobody til Ebola. Det lugter af en spin-off: http://www.sciencemagazinedigital.org/sciencemagazine/21_october_2016?pg=28#pg28
-
According to a recent update, the Genmab’s Datarumumab has yielded very positive results, which are even comparable in performance to Pharmacokinetics of Intravenous injections. The results have put Revlimid in some very serious trouble as the analyst believes that the other drug is better in almost all three areas, namely efficacy, safety and convenience.
-
Og Arzerra er ikke helt død. http://medwatch.dk/Medicinal___Biotek/article9207667.ece
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind